A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)
Amgen
Amgen
Hoffmann-La Roche
Bayer
Bristol-Myers Squibb
Merck Sharp & Dohme LLC
Day One Biopharmaceuticals, Inc.
Checkpoint Therapeutics, Inc.
Bristol-Myers Squibb
Canadian Cancer Trials Group
Bristol-Myers Squibb
PharmaMar
Hoffmann-La Roche